COVID-19 Impact on Inovio Pharmaceuticals Inc.

Pages: 29 Published: July 30, 2020 Report Code: GDHCHT149EI

  • Overview
  • Key Players
  • Contents
  • Listen

The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Inovio Pharmaceuticals Inc. performance. Inovio’s focus is on DNA-based vaccines requiring a novel route of administration

Inovio’s pipeline is most active in early-stage drug development

INO-4800 is Inovio’s COVID-19 vaccine

Funding from different sources for INO-4800


This 29-page PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

Reasons to Buy

An overview of how Inovio Pharmaceuticals Inc. will be affected by the COVID-19 pandemic.

Key Players

Inovio Pharmaceuticals Inc.

Table of Contents

1 Executive Summary

2 Company Overview

2.1 Key Stats

2.2 SWOT Analysis

2.3 Sales Forecast Overview

3 Regional Analysis

3.1 COVID-19 Spread vs. Location of Inovio Pharmaceuticals Inc. Trials

3.2 COVID-19 vs. Non-COVID-19 Trials

4 Reaction to COVID-19

4.1 INO-4800

4.2 Insight’s Exclusive Intel: Inovio Pharmaceuticals

4.3 Global Analyst Consensus Sales Forecast

4.4 Upcoming Events

4.5 Recent Deal Activity

5 Key Findings

6 Appendix

6.1 Methodology

6.2 About GlobalData

6.3 Contacts


Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.